Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction

Biomarkers

Volumn 16, Issue 7, 2011, Pages 587-589

  Moldoveanu, Elena ^a,b   Serban, Mihnea ^c   Marta, Daciana S ^a   Serban, Irina ^d   Huica, Radu ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b TITU MAIORESCU UNIVERSITY   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d CC Iliescu Emergency Institute of Cardiovascular Diseases   (Romania)

Author keywords

heart failure with preserved ejection fraction; Inflammation; lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; DISEASE EXACERBATION; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PROGNOSIS; STROKE VOLUME;

EID: 80054896732     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.611597     Document Type: Article

References (13)

1. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. (2004). Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-842. (Pubitemid 38252734)
2. Bench T, Burkhoff D, O'Connell JB, Costanzo MR, Abraham WT, St John Sutton M, Maurer MS. (2009). Heart failure with normal ejection fraction: Consideration of mechanisms other than diastolic dysfunction. Curr Heart Fail Rep 6:57-64.
3. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. (2005). Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26:137-144. (Pubitemid 40282781)
4. Corson MA, Jones PH, Davidson MH. (2008). Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101:41F-50F.
5. De Keulenaer GW, Brutsaert DL. (2008). Molecular mechanisms of diastolic dysfunction. In: Smiseth OA, Tendera M, ed. Diastolic Heart Failure. Ed. Springer, 3-20.
6. Gerber Y, Dunlay SM, Jaffe AS, McConnell JP, Weston SA, Killian JM, Roger VL. (2009). Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis 203:593-598.
7. Hogg K, Swedberg K, McMurray J. (2004). Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317-327. (Pubitemid 38167688)
8. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K. (2000). Spectrophotometric assay for serum plateletactivating factor acetylhydrolase activity. Clin Chim Acta 296:151-161. (Pubitemid 30243147)
9. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr. (2007). Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53:1652-1657. (Pubitemid 47340062)
10. Pieske B. (2011). Heart failure with preserved ejection fraction-a growing epidemic or 'The Emperor's New Clothes?'. Eur J Heart Fail 13:11-13.
11. Schmitz G, Ruebsaamen K. (2010). Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 208:10-18.
12. Tschöpe C, Westermann D. (2009). Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 34:89-96.
13. van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, Stricker BH, Witteman JC. (2006). Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study. Eur Heart J 27:2346-2352. (Pubitemid 44453579)